Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
22.24
+0.24 (1.09%)
At close: Mar 9, 2026, 4:00 PM EDT
22.16
-0.08 (-0.36%)
After-hours: Mar 9, 2026, 5:47 PM EDT
Pacira BioSciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 7.03 | -99.56 | 41.96 | 15.91 | 41.98 | Upgrade
|
| Depreciation & Amortization | 91.02 | 78.79 | 75.57 | 81 | 28.55 | Upgrade
|
| Other Amortization | 3 | 3.22 | 3.75 | 7.21 | 25.91 | Upgrade
|
| Asset Writedown & Restructuring Costs | 25.87 | 163.24 | - | 36.63 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 6.07 | -7.42 | -4.58 | 10 | - | Upgrade
|
| Stock-Based Compensation | 57.5 | 51.17 | 47.9 | 48.09 | 42.25 | Upgrade
|
| Other Operating Activities | -0.24 | 11.05 | 31.25 | -37.14 | 12.55 | Upgrade
|
| Change in Accounts Receivable | -10.74 | -7.75 | -7.16 | -2.08 | -10.43 | Upgrade
|
| Change in Inventory | -27.57 | -20.93 | -8.29 | 2.49 | -4.47 | Upgrade
|
| Change in Accounts Payable | -5.6 | 3.08 | 0.92 | 6.27 | -10.26 | Upgrade
|
| Change in Other Net Operating Assets | 5.64 | 14.5 | -26.67 | -23.11 | -0.35 | Upgrade
|
| Operating Cash Flow | 151.99 | 189.39 | 154.65 | 145.27 | 125.72 | Upgrade
|
| Operating Cash Flow Growth | -19.74% | 22.46% | 6.45% | 15.56% | 63.20% | Upgrade
|
| Capital Expenditures | -15.33 | -10.64 | -15.16 | -30.08 | -45.87 | Upgrade
|
| Cash Acquisitions | -16.7 | - | - | -32 | -424.04 | Upgrade
|
| Investment in Securities | 131.52 | -72.64 | 92.7 | -163.11 | 449.12 | Upgrade
|
| Investing Cash Flow | 99.48 | -83.28 | 77.54 | -225.19 | -20.79 | Upgrade
|
| Long-Term Debt Issued | 101 | 287.5 | 149.55 | - | 363.75 | Upgrade
|
| Long-Term Debt Repaid | -317.8 | -210.89 | -330.31 | -427.69 | - | Upgrade
|
| Net Debt Issued (Repaid) | -216.8 | 76.62 | -180.76 | -427.69 | 363.75 | Upgrade
|
| Issuance of Common Stock | 3.3 | 2.3 | 4.75 | 27.34 | 26.66 | Upgrade
|
| Repurchase of Common Stock | -153.95 | -25.49 | -0.11 | - | - | Upgrade
|
| Other Financing Activities | -2.19 | -36.06 | -6.91 | -1.18 | -9.71 | Upgrade
|
| Financing Cash Flow | -369.63 | 17.36 | -183.03 | -401.53 | 380.69 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.08 | - | - | - | - | Upgrade
|
| Net Cash Flow | -118.23 | 123.48 | 49.16 | -481.44 | 485.62 | Upgrade
|
| Free Cash Flow | 136.66 | 178.75 | 139.49 | 115.2 | 79.85 | Upgrade
|
| Free Cash Flow Growth | -23.55% | 28.15% | 21.09% | 44.27% | 103.54% | Upgrade
|
| Free Cash Flow Margin | 18.81% | 25.50% | 20.67% | 17.28% | 14.74% | Upgrade
|
| Free Cash Flow Per Share | 3.03 | 3.87 | 2.68 | 2.48 | 1.75 | Upgrade
|
| Cash Interest Paid | 15.24 | 15.42 | 27.64 | 33.3 | 7 | Upgrade
|
| Cash Income Tax Paid | 9.01 | 11 | 4.4 | 7.4 | 3.22 | Upgrade
|
| Levered Free Cash Flow | 108.56 | 163.38 | 107.15 | 92 | 49.79 | Upgrade
|
| Unlevered Free Cash Flow | 116.47 | 170.52 | 116.09 | 109.78 | 43.72 | Upgrade
|
| Change in Working Capital | -38.27 | -11.1 | -41.2 | -16.43 | -25.51 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.